US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.63

-0.4783-2.50%

Volume:31.22K

Turnover:580.13K

Market Cap:108.08M

PE:- -

High:18.69

Open:18.62

Low:18.50

Close:19.11

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:0.74

T/O Rate:0.54%

Dividend:0.71

Dividend Rate:3.84%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Beone Medicines Reports Record First Half Results with Adjusted Net Income Surge of 111%

CSPC Pharmaceutical Receives USD 10 Million AstraZeneca Milestone Payment Under Research Pact

CSPC Pharmaceutical and AstraZeneca Enter JV for Biologics Facility in China

CSPC Pharmaceutical Group Stock Falls 1.3% in Hong Kong, Underperforms Competitors

CSPC Pharma, AstraZeneca Form Biologics Manufacturing JV in China with 51%-49% Split

CSPC Pharmaceutical - Co to Hold 51% and AstraZeneca 49% in Joint Venture

THOMSON REUTERS

CSPC Pharmaceutical - Joint Venture to Manufacture Biologics Drug Substances for Global Markets

THOMSON REUTERS

Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target

CLSA: INNOVENT BIO (01801) First-Half Product Revenue Significantly Exceeds Expectations, Serving as a Positive Catalyst for Stock Price

Innovent Biologics' Product Revenue Surges 60% in Q2

MT Newswires Live

Innovent Biologics Jumps Most in 3 Weeks on Robust Product Revenue Growth

INNOVENT BIO shares open over 2% higher as first-half product revenue exceeds RMB 8.2 billion, marking a 55% surge

Hong Kong Listed Companies' News Digest: Innovent Bio's First-Half Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% Year-on-Year

Innovent Biologics Says First Half 2026 Product Revenue Exceeds Rmb8.2 Billion

Innovent Biologics - First Half 2026 Product Revenue Exceeds Rmb8.2 Bln, up over 55% Y/Y

THOMSON REUTERS

CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live

CSPC Says NMPA Accepts NDA for Anbenitamab, Albumin-Bound Docetaxel Neoadjuvant Breast Cancer Combo Under Priority Review

Alphamab Oncology Says NMPA Accepts NDA for Anbenitamab (kn026)

Wuxi Biologics (Cayman) Stock Climbs 4.3% in Hong Kong

CRO Stocks Surge: Multiple Overseas MNCs and CXO Firms Report Strong Interim Results, Raise Full-Year Guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/KURE/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.6317,"timestamp":1787594139819,"preClose":19.11,"halted":0,"volume":31224,"delay":0,"changeRate":-0.0250287807430665,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Trading","change":-0.4783,"latestTime":"08-24 13:56:03 EDT","open":18.615,"high":18.69,"low":18.5,"amount":580132.86504,"amplitude":0.009942,"askPrice":18.6,"askSize":6200,"bidPrice":18.37,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.11,"sharesOutstanding":4750002,"nav":18.99,"aum":110160584.96,"dividendRate":0.038365,"bidAskSpread":0.003071,"preHourTrading":{"tag":"盘前","latestPrice":18.5,"preClose":19.11,"latestTime":"07:56 EDT","volume":54,"amount":998.020008,"timestamp":1787572607542,"change":-0.61,"changeRate":-0.03192,"amplitude":0.005128},"postHourTrading":{"tag":"盘后","latestPrice":19.33,"preClose":19.11,"latestTime":"19:13 EDT","volume":111,"amount":2143.44,"timestamp":1787353996933,"change":0.22,"changeRate":0.011512,"amplitude":0.011512},"volumeRatio":0.740952,"impliedVol":0.3186,"impliedVolPercentile":0.6574},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.740952,"shares":5800979,"dividePrice":0.7148,"high":18.69,"amplitude":0.009942,"preClose":19.11,"low":18.5,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.6317,"committee":-0.850746,"eps":0,"divideRate":0.038365,"volume":31224,"delay":0,"ttmEps":0,"open":18.615,"prevYearClose":17.04,"prevWeekClose":19.11,"prevMonthClose":17.28,"prevQuarterClose":15.747,"fiveDayClose":18.6,"twentyDayClose":17.3752,"sixtyDayClose":15.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1138012620","title":"Beone Medicines Reports Record First Half Results with Adjusted Net Income Surge of 111%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138012620","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138012620?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:18","pubTimestamp":1785925103,"startTime":"0","endTime":"0","summary":"Beone Medicines Ltd (stock code: 06160) has released its financial results for the second quarter of fiscal year 2026, showcasing robust performance. For the second quarter, the company's global...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1251922891.USD","BK4139","LU1770034418.SGD","BK0239","LU1303224171.USD","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","KURE","ONC","BK1588","BK4526","BK4585","BK1500","LU0307460666.USD","06160","LU1719994722.HKD","BK1583","BK1161","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657837510","title":"CSPC Pharmaceutical Receives USD 10 Million AstraZeneca Milestone Payment Under Research Pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2657837510","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657837510?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:51","pubTimestamp":1785923488,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical receives USD 10 million AstraZeneca milestone payment under research pactCSPC received a USD 10 million milestone payment from AstraZeneca on Aug. 5, 2026 under their strategic res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7Ml65f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0969580561.USD","BK1515","IE00BZ08YS42.EUR","LU2108987350.USD","LU1008478684.HKD","LU1807302812.USD","LU0949170772.SGD","LU1923622614.USD","LU2089984988.USD","LU1119994496.HKD","LU0784385840.USD","LU0314109678.HKD","LU1481600234.SGD","IE00B2B36J28.USD","LU1496350171.SGD","LU2089283258.USD","LU1153585028.USD","LU1267930573.SGD","LU1003076772.USD","LU0889566641.SGD","LU0501845795.SGD","LU1323610961.USD","LU1057294990.SGD","AZN.UK","LU2468319806.SGD","LU0792757196.USD","LU0857590862.USD","LU1226287875.USD","LU1989772923.USD","03165","01093","LU1983299246.USD","IE00B031HY20.USD","LU0499090636.EUR","LU1226288253.USD","LU0640478417.SGD","LU0029864427.USD","LU0823399737.USD","LU1152091168.USD","LU2039709279.SGD","LU2355687059.USD","LU1951186391.HKD","LU2433249047.HKD","LU0823416689.USD","LU1813983027.USD","LU1152091754.HKD","LU0997586515.USD","LU1226287529.USD","LU1880407215.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657151172","title":"CSPC Pharmaceutical and AstraZeneca Enter JV for Biologics Facility in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2657151172","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657151172?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:32","pubTimestamp":1785918767,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical And AstraZeneca Enter JV For Biologics Facility In ChinaAug 5 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:PHARMA AND ASTRAZENECA ENTER JOINT VENTURE FOR BIOLOGICS FACI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420VA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00B5MMRT66.SGD","LU1267930813.SGD","LU2468319806.SGD","LU0920840948.USD","LU0432979614.USD","LU2237443978.SGD","LU0757432116.USD","LU0315179316.USD","IE00B2B36J28.USD","LU1487256676.USD","LU1813983027.USD","LU1291159041.SGD","LU0882574055.USD","LU2293690082.USD","LU1880407215.USD","LU2237443622.USD","IE00B3T34201.USD","IE0002141913.USD","03165","LU0128525929.USD","LU0289739699.SGD","LU1226288253.USD","LU0345777659.USD","AZN.UK","LU1003076772.USD","LU0058720904.USD","LU0211326755.USD","LU2089984988.USD","LU1863844749.USD","LU2039709279.SGD","LU2114397693.USD","LU0310799852.SGD","IE00BZ08YS42.EUR","LU0390134368.USD","LU1993786604.SGD","LU1061106388.HKD","LU0784385840.USD","SG9999001176.USD","LU1814569148.SGD","01093","LU0708994859.HKD","LU0969580561.USD","IE00BKPKM643.USD","LU1481599808.USD","BK5011","LU0072913022.USD","KURE","IE0034235188.USD","LU0314109678.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511079","title":"CSPC Pharmaceutical Group Stock Falls 1.3% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511079?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:32","pubTimestamp":1785918720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slipped 1.3% to 8.38 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25915.82.CSPC Pharmaceutical Group Ltd. closed 28% below its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 1.2%, SSY Group Ltd. fell 0.2%, and United Laboratories International Holdings Ltd. rose 0.3%.Trading volume totaled 74.5 million shares, compared to the 50-day average of 106.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","IE0008368742.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1328277881.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1813983027.USD","SG9999004220.SGD","LU1951186391.HKD","LU0314109678.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1515","LU1226288170.HKD","BK1191","LU1226288253.USD","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU1993786604.SGD","LU1226287875.USD","LU1807302812.USD","LU1226287792.SGD","HK0000165453.HKD","IE00B031HY20.USD","LU0315179316.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","LU1226287529.USD","LU0067412154.USD","IE0008369823.USD","LU1008478684.HKD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657751179","title":"CSPC Pharma, AstraZeneca Form Biologics Manufacturing JV in China with 51%-49% Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2657751179","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657751179?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:31","pubTimestamp":1785918683,"startTime":"0","endTime":"0","summary":"CSPC Pharma, AstraZeneca form biologics manufacturing JV in China with 51%-49% splitCSPC Pharmaceutical entered a joint venture contract with AstraZeneca to build a next-generation biologics manufactu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL2sdnL0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1960683339.HKD","LU1323610961.USD","LU2114397693.USD","LU1481600234.SGD","AZN.UK","LU0784385170.HKD","LU0390134368.USD","01093","LU0575583348.USD","LU1003076772.USD","LU1057294990.SGD","SG9999001176.USD","LU0496365809.HKD","LU0314109678.HKD","LU0708994859.HKD","LU0501845795.SGD","LU1814569148.SGD","LU1019634622.SGD","LU0310800965.SGD","SG9999004220.SGD","IE0034235188.USD","LU0545039389.USD","LU0661504455.SGD","IE0008369823.USD","IE0008368742.USD","LU1807302812.USD","LU0823416689.USD","LU2237443465.HKD","LU2237443622.USD","LU0211326839.USD","LU2355687059.USD","LU1119994496.HKD","LU1226287529.USD","LU0792757196.USD","IE00BFTCPJ56.SGD","LU1487256676.USD","LU0058720904.USD","LU1813983027.USD","LU0171293334.USD","KURE","LU2125909247.SGD","LU1046234339.USD","LU1015430645.USD","LU1267930813.SGD","LU1880407215.USD","03165","HK0000165453.HKD","LU0203347892.USD","LU0640478417.SGD","LU0889565080.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511223","title":"CSPC Pharmaceutical - Co to Hold 51% and AstraZeneca 49% in Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511223?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918645,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420VA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","IE0008369823.USD","BK1191","LU0880133367.SGD","LU1328277881.USD","IE0008368742.USD","01093","LU1951186391.HKD","LU1960683339.HKD","LU2039709279.SGD","LU0314109678.HKD","IE00B543WZ88.USD","LU1226288253.USD","KURE","LU1008478684.HKD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0315179316.USD","BK1521","LU1807302812.USD","LU1152091168.USD","LU1226287529.USD","LU0140636845.USD","LU1226288170.HKD","LU0067412154.USD","BK1515","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1152091754.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1226287792.SGD","SG9999004220.SGD","LU1993786604.SGD","LU0072913022.USD","LU1226287875.USD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657112205","title":"CSPC Pharmaceutical - Joint Venture to Manufacture Biologics Drug Substances for Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2657112205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657112205?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918645,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420VA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01093","BK1515","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","KURE","LU0067412154.USD","LU1226287875.USD","IE0008368742.USD","LU1226288253.USD","LU1152091168.USD","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","BK1521","LU0314109678.HKD","LU1008478684.HKD","LU0315179316.USD","SG9999004220.SGD","LU1807302812.USD","LU1960683339.HKD","LU2039709279.SGD","LU0072913022.USD","LU0140636845.USD","LU1328277881.USD","LU1226288170.HKD","LU1226287792.SGD","LU1951186391.HKD","IE0008369823.USD","LU1226287529.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE00B543WZ88.USD","LU1813983027.USD","LU1152091754.HKD","LU1993786604.SGD","LU0501845795.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107154360","title":"Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1107154360","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107154360?lang=en_us&edition=fundamental","pubTime":"2026-08-05 15:01","pubTimestamp":1785913278,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801.HK) reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","BK4207","LU0648001328.SGD","IYF","LU2097828714.EUR","LU0310800965.SGD","LU1074936037.SGD","LU0098860793.USD","LU0162691827.USD","LU0314106906.USD","LU0980610538.SGD","LU1366192091.USD","EWH","LU1506573853.SGD","LU1969619763.USD","BK4566","LU0106831901.USD","LU1244550221.USD","LU2456880835.USD","LU2236285917.USD","C","LU0128525689.USD","LU2125154778.USD","BK4534","KURE","LU2417539215.USD","LU2462157665.USD","LU0320765646.SGD","LU1244550494.USD","LU2360032135.SGD","LU1791807156.HKD","LU1201861249.SGD","LU0203347892.USD","BK4585","LU2097828474.EUR","LU0072461881.USD","BK4504","BK4588","BK1589","LU0502904849.HKD","BK1583","LU2097828557.USD","TFNS","LU0455707207.USD","BK1161","FTXO","01801","LU1668664300.SGD","LU2488822045.USD","LU2097828805.USD","LU0052756011.USD","LU2328871848.SGD","LU1244550577.SGD","LU1162221912.USD","LU1267930227.SGD","LU2242644610.SGD","LU0170899867.USD","LU0130517989.USD","BK4559","HK0000165453.HKD","LU0477156953.USD","LU2097828631.EUR","LU2125154935.USD","LU0203345920.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154699784","title":"CLSA: INNOVENT BIO (01801) First-Half Product Revenue Significantly Exceeds Expectations, Serving as a Positive Catalyst for Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1154699784","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154699784?lang=en_us&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913218,"startTime":"0","endTime":"0","summary":"CLSA has released a research report indicating that INNOVENT BIO (01801) reported product revenue of RMB 8.2 billion for the first half of 2026, representing a 55% year-on-year increase and far...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2488822045.USD","BK1583","LU0455707207.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","LU2097828631.EUR","LU2242644610.SGD","BK1161","LU2097828805.USD","LU2328871848.SGD","LU2097828714.EUR","KURE","HK0000165453.HKD","BK1589","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657910915","title":"Innovent Biologics' Product Revenue Surges 60% in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2657910915","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657910915?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:08","pubTimestamp":1785899286,"startTime":"0","endTime":"0","summary":"Innovent Biologics  said second-quarter product revenue exceeded 4.3 billion yuan, up about 60% from a year earlier, according to a Wednesday Hong Kong bourse filing.First-half product revenue topped 8.2 billion yuan, representing year-over-year growth of more than 55%.The growth was driven by strong sales of flagship products, including mazdutide, as well as broader market penetration of its tyrosine kinase inhibitor therapies included in China's National Reimbursement Drug List.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828805.USD","KURE","LU2097828474.EUR","01801","HK0000165453.HKD","LU2097828631.EUR","LU0502904849.HKD","LU2097828714.EUR","LU2242644610.SGD","BK1589","LU1969619763.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","BK1583","LU2097828557.USD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657606599","title":"Innovent Biologics Jumps Most in 3 Weeks on Robust Product Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2657606599","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657606599?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:52","pubTimestamp":1785894772,"startTime":"0","endTime":"0","summary":"BUZZ-Innovent Biologics jumps most in 3 weeks on robust product revenue growth** Shares of Innovent Biologics Inc1801.HKjump 6.3% to HK$92.2, on track for the biggest one-day pct gain since July 15** Stock touches the highest level since July 24 in the second session of gain** The innovative medicine developer and producer says itsfirst half 2026 product revenueexceeds 8.2 bln yuan , up over 55% y/y, of which total revenue for the second quarter is up 60% y/y to over 4.3 bln yuan** YTD, stock up 18%, Hang Seng Biotech Index.HSBIOup 0.6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N44201W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","KURE","LU2328871848.SGD","LU2097828631.EUR","01801","LU2097828474.EUR","LU2097828714.EUR","BK1589","BK1583","BK1161","LU1969619763.USD","LU2488822045.USD","LU0455707207.USD","LU2097828805.USD","HK0000165453.HKD","LU0502904849.HKD","LU2242644610.SGD","LU2097828557.USD","01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189813572","title":"INNOVENT BIO shares open over 2% higher as first-half product revenue exceeds RMB 8.2 billion, marking a 55% surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1189813572","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189813572?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:34","pubTimestamp":1785893690,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) opened more than 2% higher in Hong Kong trading, with shares climbing 2.48% to HKD 88.85 as of press time, recording a turnover of HKD 13.83 million.According to a company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2242644610.SGD","LU0502904849.HKD","KURE","BK4585","KCAI","LU2488822045.USD","LU2097828805.USD","LU2097828557.USD","BK1589","BK1583","LU2097828714.EUR","01801","HK0000165453.HKD","BK1161","BK4588","LU2328871848.SGD","LU0455707207.USD","LU2097828474.EUR","LU2097828631.EUR","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107103839","title":"Hong Kong Listed Companies' News Digest: Innovent Bio's First-Half Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1107103839","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107103839?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:18","pubTimestamp":1785892701,"startTime":"0","endTime":"0","summary":"Innovent Bio (01801) reported that its first-half product revenue surpassed RMB 8.2 billion, reflecting a year-on-year increase of more than 55%.Major DevelopmentsSEYOND (02665) has signed a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1105","LU2242644610.SGD","LU0502904849.HKD","06951","KURE","02270","BK1144","08646","BK4585","BK1229","KCAI","LU2488822045.USD","LU2097828805.USD","BK1170","LU2097828557.USD","BK1589","BK1583","01801","BK4588","HK0000165453.HKD","BK1161","LU2097828714.EUR","LU2328871848.SGD","LU0455707207.USD","LU2097828474.EUR","02665","LU2097828631.EUR","VXUS","BK1258"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596147","title":"Innovent Biologics Says First Half 2026 Product Revenue Exceeds Rmb8.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596147","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657596147?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:16","pubTimestamp":1785892580,"startTime":"0","endTime":"0","summary":"BRIEF-Innovent Biologics Says First Half 2026 Product Revenue Exceeds RMB8.2 BillionAug 5 (Reuters)-Innovent Biologics Inc1801.HK:FIRST HALF 2026 PRODUCT REVENUE EXCEEDS RMB8.2 BILLION, UP OVER 55% Y/YFurther company coverage:1801.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4411GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2328871848.SGD","LU2488822045.USD","LU2242644610.SGD","LU2097828557.USD","LU1969619763.USD","KURE","BK1589","BK1161","LU2097828714.EUR","LU0502904849.HKD","01801","LU0455707207.USD","BK1583","LU2097828805.USD","LU2097828631.EUR","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593492","title":"Innovent Biologics - First Half 2026 Product Revenue Exceeds Rmb8.2 Bln, up over 55% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657593492?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:01","pubTimestamp":1785888088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4411GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0502904849.HKD","LU2097828631.EUR","BK1589","KURE","LU2488822045.USD","BK1161","LU2097828805.USD","LU2328871848.SGD","LU2242644610.SGD","BK1583","LU1969619763.USD","LU0455707207.USD","LU2097828474.EUR","LU2097828714.EUR","HK0000165453.HKD","LU2097828557.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558078","title":"CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558078","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558078?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:34","pubTimestamp":1785843297,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said a new drug application for Anbenitamab was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application for Anbenitamab, co-developed by Shanghai JMT-Bio Technology, a unit of the company, and Alphamab Oncology , has also been included in the priority review and approval procedures.The indication for the application is Anbenitamab in combination with docetaxel  ± carboplatin as neoadjuvant therapy to treat breast cancer in adults.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0314109678.HKD","LU1226287792.SGD","LU1226287875.USD","LU1813983027.USD","LU1008478684.HKD","01093","LU1152091168.USD","BK1574","IE0008368742.USD","09966","IE00B5MMRT66.SGD","LU0072913022.USD","LU1960683339.HKD","BK1161","LU0501845795.SGD","LU1226288170.HKD","IE0008369823.USD","IE00B031HY20.USD","LU0326950275.SGD","SG9999004220.SGD","LU1807302812.USD","LU1993786604.SGD","BK1191","LU1226287529.USD","IE00BZ08YR35.GBP","LU0067412154.USD","LU1226288253.USD","LU1328277881.USD","LU1951186391.HKD","HK0000165453.HKD","LU0880133367.SGD","BK1521","KURE","IE00B543WZ88.USD","LU1152091754.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","BK1515","LU0140636845.USD","LU0315179316.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656053422","title":"CSPC Says NMPA Accepts NDA for Anbenitamab, Albumin-Bound Docetaxel Neoadjuvant Breast Cancer Combo Under Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2656053422","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656053422?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:12","pubTimestamp":1785838361,"startTime":"0","endTime":"0","summary":"CSPC says NMPA accepts NDA for anbenitamab, albumin-bound docetaxel neoadjuvant breast cancer combo under priority reviewCSPC said China’s NMPA accepted an NDA for anbenitamab (KN026) with its albumin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL1080Md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951186391.HKD","SG9999004220.SGD","LU1993786604.SGD","LU1960683339.HKD","LU0880133367.SGD","01093","IE00B543WZ88.USD","IE0008369823.USD","IE00BZ08YT58.USD","LU0067412154.USD","LU1813983027.USD","LU1226287529.USD","KURE","LU0315179316.USD","BK1521","LU1328277881.USD","LU0140636845.USD","LU1226287792.SGD","LU1226287875.USD","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YS42.EUR","BK1515","LU2039709279.SGD","LU1807302812.USD","LU1008478684.HKD","IE0008368742.USD","BK1191","LU0072913022.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1152091754.HKD","IE00B031HY20.USD","LU1226288253.USD","HK0000165453.HKD","LU0314109678.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656153495","title":"Alphamab Oncology Says NMPA Accepts NDA for Anbenitamab (kn026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656153495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656153495?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:04","pubTimestamp":1785837881,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)Aug 4 (Reuters)-Alphamab Oncology9966.HK:NMPA ACCEPTS NDA FOR ANBENITAMAB (KN026) AS NEOADJUVANT HER2+ BREAST CANCER TREATMENTFurther company coverage:9966.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","BK1515","LU0067412154.USD","LU0140636845.USD","LU1226287792.SGD","LU2039709279.SGD","LU1152091168.USD","LU1328277881.USD","KURE","LU1152091754.HKD","IE0008369823.USD","HK0000165453.HKD","LU1993786604.SGD","IE00BZ08YT58.USD","BK1574","BK1191","BK1521","LU1226287529.USD","LU1226287875.USD","BK1161","SG9999004220.SGD","LU0880133367.SGD","LU1008478684.HKD","LU0315179316.USD","IE0008368742.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1813983027.USD","IE00BZ08YR35.GBP","LU0072913022.USD","LU0326950275.SGD","LU1226288253.USD","01093","LU1807302812.USD","LU1960683339.HKD","09966","LU0501845795.SGD","LU0314109678.HKD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656368565","title":"Wuxi Biologics (Cayman) Stock Climbs 4.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2656368565","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656368565?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:31","pubTimestamp":1785832260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 4.3% to 40.46 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.6% to 25852.92.This was the stock's third consecutive day of gains.Wuxi Biologics  Inc. closed 8.0% short of its 52-week high of HK$44.00, which the company achieved Feb. 12.Trading volume totaled 49.1 million shares, compared to the 50-day average of 31.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU0320764599.SGD","LU0039217434.USD","SG9999002463.SGD","LU0819121731.USD","LU0348735423.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU0359201612.USD","LU0516422952.EUR","LU0979878070.USD","LU0456827905.SGD","BK1610","LU0456846285.SGD","KURE","LU0823426480.USD","LU1720050803.USD","BK1521","LU0140636845.USD","LU1242518857.USD","02269","LU0516423091.SGD","LU0348825331.USD","LU1688375341.USD","LU0516422366.SGD","LU0307460666.USD","LU3063872942.SGD","LU0181495838.USD","LU0516423174.USD","LU0588546209.SGD","LU0327786744.USD","LU0043850808.USD","LU2039709279.SGD","LU1242518931.SGD","LU0572944931.SGD","LU0516422440.USD","LU0359202008.SGD","LU0051755006.USD","BK1576","BK1589","LU0417516738.SGD","SG9999002562.SGD","LU1880383366.USD","LU0417516902.SGD","LU0326950275.SGD","LU0052750758.USD","LU1794554557.SGD","LU0856984785.SGD","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178493143","title":"CRO Stocks Surge: Multiple Overseas MNCs and CXO Firms Report Strong Interim Results, Raise Full-Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1178493143","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178493143?lang=en_us&edition=fundamental","pubTime":"2026-08-04 11:08","pubTimestamp":1785812902,"startTime":"0","endTime":"0","summary":"Shares of CRO concept stocks are leading gains in Hong Kong trading. As of writing, WUXI APPTEC (02359) has surged 11.05% to HKD 180.9, GENSCRIPT BIO (01548) is up 10.18% to HKD 17.96, ASYMCHEM...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0051755006.USD","VXUS","HK0000306701.USD","LU0320764599.SGD","BK1583","02359","LU0456846285.SGD","BK1610","LU1794554557.SGD","LU1880383366.USD","LU0456827905.SGD","LU1046422090.SGD","LU0359202008.SGD","LU0417516902.SGD","BK4588","LU0348735423.USD","BK1589","LU1242518857.USD","LU1242518931.SGD","LU2125910500.SGD","SG9999002562.SGD","HK0000320264.USD","KURE","WX","LU0588546209.SGD","LU0348766576.USD","HK0000320223.HKD","LU0326950275.SGD","LU2039709279.SGD","LU0039217434.USD","BK1576","KCAI","LU0140636845.USD","LU0307460666.USD","SG9999002463.SGD","LU2045819591.USD","LU0819121731.USD","LU0052750758.USD","02269","LU0516423174.USD","LU1720050803.USD","LU0516422366.SGD","LU0348825331.USD","LU0516422952.EUR","LU0572944931.SGD","LU0327786744.USD","LU0856984785.SGD","LU0979878070.USD","BK4585","LU0359201612.USD","LU0417516738.SGD","BK1191","LU0516423091.SGD","LU0823426308.USD","LU0823426480.USD","LU0708995583.HKD","LU3063872942.SGD","LU1688375341.USD","IE00B0JY6N72.USD","CXO","BK1521","LU0181495838.USD","LU0516422440.USD","HK0000306685.HKD","LU2242644610.SGD","06821","LU0348767384.USD","BK1141","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}